Map Home
Type / to search with text or keywords
/
keyboard shortcut: Type "/" on your keyboard for a quick search
Search button
Loading...
Loading...
Scroll left
Grants
Citations
H-Index
Patents
News
Books
Scroll right
Collapse sidebar
Data issues & feedback
Adjust height of sidebar
KMap
People
Adjust height of sidebar
KMap
Profile
Kirsten Anderson
Senior Coordinator, Regulatory
Senior VP Health Sciences
Overview
Research
More
Collaboration
(55)
Francisco Moreno
Mutual work: 1 Proposal﹒1 Grant
Collaboration Details
Emmanuel Katsanis
Mutual work: 1 Proposal﹒1 Grant
Collaboration Details
Bruce Coull
Mutual work: 4 Grants﹒8 Proposals
Collaboration Details
Jordan Karp
Mutual work: 2 Grants﹒4 Proposals
Collaboration Details
Sachin Chaudhary
Mutual work: 3 Grants
Collaboration Details
Page 1 of 11
Previous page
Next page
Grants
(40)
Protocol Title: A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in Subjects with Acute Ischemic Stroke (AIS)
Active
·
2024
·
$0 / $370.5K
·
External
undefined (CD)
stroke,
drug efficacy,
safety evaluation,
clinical trial,
ischemic stroke
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency?associated Liver Disease With Metavir
Active
·
2023
·
$0 / $1.6M
·
External
undefined (CD)
clinical trial,
liver disease,
alpha-1 antitrypsin,
treatment,
safety
A First-in-human (FIH) Study of Inhibitory Interneurons (NRTX-1001) in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE)
Active
·
2023
·
$0 / $749.8K
·
External
undefined (CD)
neuroscience,
epilepsy,
clinical trial,
drug resistance,
inhibitory interneurons
TRANSFORM: A 52-week, Randomized, Placebo-controlled, Double-blind, Adaptive Phase 2b/3 Trial of Setanaxib with a 52-week Extension Phase in Patients with Primary Biliary Cholangitis (PBC) and Elevate
Active
·
2023
·
$0 / $641.6K
·
External
undefined (CD)
clinical trial,
drug therapy,
liver disease,
biomarker,
immunology
Phase 1/2a Dose Escalation Study of ANPD001 in Sporadic Parkinson Disease
Active
·
2023
·
$0 / $597.6K
·
External
undefined (CD)
parkinson's disease,
dose escalation,
clinical trial,
neurodegenerative diseases
Page 1 of 8
Previous page
Next page